Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial Support
This activity is supported by an educational grant from Seagen, Inc.
Oncology Consultations®: Addressing the Risk and Burden of CNS Metastases in HER2+ Breast Cancer to Improve Patient Outcomes
Release Date: December 23, 2021
Expiration Date: December 23, 2022
This online case-based educational activity features 2 key clinical experts discussing clinical scenarios of patients with HER2+ MBC with brain metastasis. The faculty will review data for management of brain metastases secondary to breast cancer, discuss how treatment of this challenging complication can be advanced, and demonstrate how current therapies can be optimized and individualized to improve patient care.
Acknowledgement of Commercial SupportThis activity is supported by an educational grant from Seagen, Inc..
Instructions for This Activity and Receiving Credit
You may immediately download your certificate.
Upon successful completion of this activity, you should be better prepared to:
- Determine the biology of brain metastases arising from breast cancer, the therapeutic implications of the blood-brain barrier, and subtype-specific differences in propensity for CNS metastases among patients with advanced HER2-positive breast cancer
- Personalize treatment for patients with advanced HER2-positive breast cancer and brain metastases by selecting appropriate systemic and local approaches
- Utilize evidence-based multidisciplinary team approaches to optimize treatment outcomes in patients with brain metastases from breast cancer
- Explain emerging strategies for the treatment of HER2-positive breast cancer brain metastases and their potential impact on evolving treatment paradigms
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
Professor of Medicine
Director, Breast Cancer Clinical Trials Program
Division of Hematology-Oncology
David Geffen School of Medicine
Medical Director, Jonsson Comprehensive Cancer Center Clinical Research Unit
University of California
Los Angeles, CA
Disclosures: Grant/Research Support: Ambrx, Amgen, Arvinas, Bayer, Daiichi-Sankyo, Dignitana, Genentech, GSK, Immunomedics, Lilly, MacroGenics, Novartis, OBI Pharma, Pfizer, Pieris Pharmaceuticals, Puma Biotechnology, Radius Health, Roche, Sanofi, Seagen, Inc.; Stock/Shareholder: NKMAX; Other Support: Travel: Lilly.
Professor of Medicine
Deputy Head, Division of Medical Oncology
Director, Breast Cancer Research Program &
Young Women’s Breast Cancer Translational Program
University of Colorado Anschutz Medical Center
Disclosures: Consultant: AstraZeneca, Daiichi-Sankyo, Seagen Inc., Consultant: AstraZeneca, Seagen Inc.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.